Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michele Azada

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 18, 2011
Asymptomatic profound sinus bradycardia (heart rate ≤45) in non-small cell lung cancer patients treated with crizotinibSai-Hong Ignatius Ou, Michele Azada, Joni Dy, et al.
Cancer|March 19, 2013
Heart rate decrease during crizotinib treatment and potential correlation to clinical responseSai-Hong Ignatius Ou, Wilson P Tong, Michele Azada, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 14, 2014
Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to AlectinibSai-Hong Ignatius Ou, Samuel J Klempner, Joel R Greenbowe, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 17, 2014
Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinibSai-Hong Ignatius Ou, Michele Azada, David J Hsiang, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 18, 2011
Asymptomatic profound sinus bradycardia (heart rate ≤45) in non-small cell lung cancer patients treated with crizotinibSai-Hong Ignatius Ou, Michele Azada, Joni Dy, et al.
Cancer|March 19, 2013
Heart rate decrease during crizotinib treatment and potential correlation to clinical responseSai-Hong Ignatius Ou, Wilson P Tong, Michele Azada, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 14, 2014
Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to AlectinibSai-Hong Ignatius Ou, Samuel J Klempner, Joel R Greenbowe, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 17, 2014
Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinibSai-Hong Ignatius Ou, Michele Azada, David J Hsiang, et al.
Pageof 1